Advances and challenges of artificial intelligence in postoperative follow-up management of lung cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHANG Ying ¹ , ZHOU Jian ² , ZHANG Yaoxi ² , PU Qiang ² ,  LIU Lunxu ²

1. Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;
2. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China;

Corresponding?author：

LIU Lunxu, Email: lunxu_liu@aliyun.com

Keywords：

Artificial intelligence; lung cancer; follow-up management; recurrence prediction; patient-reported outcomes; digital health

DOI：

10.7507/1007-4848.202605027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Artificial intelligence (AI) has made preliminary advances in the management of postoperative follow-up for lung cancer; however, a systematic review of its application value across the entire follow-up continuum remains lacking. Taking the four core dimensions of postoperative follow-up management as its framework, including surveillance candidate selection, follow-up interval optimization, follow-up protocol design, and follow-up modality selection, this review examines the progress of AI in patient risk stratification, surveillance frequency optimization, content design, and supportive platform development. The review further delineates the current challenges and future directions for AI in this domain, and ultimately seeks to promote the standardized and scaled application of AI in postoperative follow-up management for lung cancer, with the goal of establishing a "care beyond hospitalization" life-cycle management framework that improves the long-term quality of survival for patients undergoing lung cancer surgery.

1.	Leivaditis V, Maniatopoulos AA, Lausberg H, et al. Artificial intelligence in thoracic surgery: a review bridging innovation and clinical practice for the next generation of surgical care[J]. J Clin Med, 2025, 14(8): 2729.
2.	Huang D, Li Z, Jiang T, et al. Artificial intelligence in lung cancer: current applications, future perspectives, and challenges[J]. Front Oncol, 2024, 14: 1486310.
3.	Gandhi Z, Gurram P, Amgai B, et al. Artificial intelligence and lung cancer: impact on improving patient outcomes[J]. Cancers (Basel), 2023, 15(21): 5236.
4.	Lococo F, Ghaly G, Flamini S, et al. Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives[J]. J Thorac Dis, 2024, 16(10): 7096-7110.
5.	Li Y, Chai X, Yang M, et al. Accurate prediction of disease-free and overall survival in non-small cell lung cancer using patient-level multimodal weakly supervised learning[J]. NPJ Precis Oncol, 2025, 9(1): 197.
6.	Jung HA, Lee DY, Park BG, et al. Deep-learning model for real-time prediction of recurrence in early-stage non-small cell lung cancer: a multimodal approach (RADAR CARE Study)[J]. JCO Precis Oncol, 2025, 9: e2500172.
7.	Jin Y, Mu W, Shi Y, et al. Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG)[J]. EClinicalMedicine, 2024, 75: 102769.
8.	Baptiste JV. Process improvement for clinical follow-up of incidental lung nodules: a practical perspective[J]. Chest, 2026, 169(4): 1135-1141.
9.	Heiden BT, Eaton DB, Chang SH, et al. Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer[J]. J Natl Cancer Inst, 2023, 115(3): 303-310.
10.	Jin W, Shen L, Tian Y, et al. Improving the prediction of spreading through air spaces (STAS) in primary lung cancer with a dynamic dual-delta hybrid machine learning model: a multicenter cohort study[J]. Biomark Res, 2023, 11(1): 102.
11.	Sasaki Y, Kondo Y, Aoki T, et al. Use of deep learning to predict postoperative recurrence of lung adenocarcinoma from preoperative CT[J]. Int J Comput Assist Radiol Surg, 2022, 17(9): 1651-1661.
12.	Akram F, Wolf JL, Trandafir TE, et al. Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies[J]. Lung Cancer, 2023, 186: 107413.
13.	Shimada Y, Kudo Y, Maehara S, et al. Artificial intelligence-based radiomics for the prediction of nodal metastasis in early-stage lung cancer[J]. Sci Rep, 2023, 13(1): 1028.
14.	Kinoshita F, Takenaka T, Yamashita T, et al. Development of artificial intelligence prognostic model for surgically resected non-small cell lung cancer[J]. Sci Rep, 2023, 13(1): 15683.
15.	Pu L, Dhupar R, Meng X. Predicting postoperative lung cancer recurrence and survival using Cox proportional hazards regression and machine learning[J]. Cancers (Basel), 2024, 17(1): 33.
16.	Na KJ, Kim YT, Goo JM, et al. Clinical utility of a CT-based AI prognostic model for segmentectomy in non-small cell lung cancer[J]. Radiology, 2024, 311(1): e231793.
17.	Tominaga M, Yamazaki M, Umezu H, et al. Prognostic value and pathological correlation of peritumoral radiomics in surgically resected non-small cell lung cancer[J]. Acad Radiol, 2024, 31(9): 3801-3810.
18.	Zhao X, Wang Y, Xue M, et al. Preoperative assessment of tertiary lymphoid structures in stage Ⅰ lung adenocarcinoma using CT radiomics: a multicenter retrospective cohort study[J]. Cancer Imaging, 2024, 24(1): 167.
19.	Sujit SJ, Aminu M, Karpinets TV, et al. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights[J]. Nat Commun, 2024, 15(1): 3152.
20.	Niu Y, Xie HB, Jia HB, et al. Multimodal deep learning integrating tumor radiomics and mediastinal adiposity improves survival prediction in non-small cell lung cancer: a prognostic modeling study[J]. Cancer Med, 2025, 14(15): e71077.
21.	Amini M, Hajianfar G, Salimi Y, et al. MetaPredictomics: a comprehensive approach to predict postsurgical non-small cell lung cancer recurrence using clinicopathologic, radiomics, and organomics data[J]. Clin Nucl Med, 2025, 50(12): 1130-1143.
22.	Yan H, Niimi T, Matsunaga T, et al. Preoperatively predicting survival outcome for clinical stage ⅠA pure-solid non-small cell lung cancer by radiomics-based machine learning[J]. J Thorac Cardiovasc Surg, 2025.
23.	Janik A, Torrente M, Costabello L, et al. Machine learning-assisted recurrence prediction for patients with early-stage non-small-cell lung cancer[J]. JCO Clin Cancer Inform, 2023, 7: e2200062.
24.	王志林, 朱曉雷, 張瀟文, 等. 人工智能在非小細胞肺癌病理學和預后中應用的研究進展[J]. 中國胸心血管外科臨床雜志, 2022, 29(9): 1223-1229.Wang ZL, Zhu XL, Zhang XW, et al. Research progress on the application of artificial intelligence in the pathology and prognosis of non-small cell lung cancer[J]. Chin J Clin Thorac Cardiovasc Surg, 2022, 29(9): 1223-1229.
25.	馮時, 滕曉東. 人工智能在肺癌病理精準診斷中的研究進展[J]. 中國胸心血管外科臨床雜志, 2021, 28(5): 592-596.Feng S, Teng XD. Research progress on artificial intelligence in precise pathological diagnosis of lung cancer[J]. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(5): 592-596.
26.	Mehri-Kakavand G, Mdletshe S, Wang A. A comprehensive review on the application of artificial intelligence for predicting postsurgical recurrence risk in early-stage non-small cell lung cancer using computed tomography, positron emission tomography, and clinical data[J]. J Med Radiat Sci, 2025, 72(3): 280-296.
27.	Zhang D, Wu Y, Xu Y, et al. Development of a postoperative recurrence prediction model for stage Ⅰ non-small cell lung cancer patients using multimodal data based on machine learning[J]. J Army Med Univ, 2025, 47(14): 1602-1611.
28.	Kwok WC, Ma TF, Ho JCM, et al. Prediction model on disease recurrence for low risk resected stageⅠ lung adenocarcinoma[J]. Respirology, 2023, 28(7): 669-676.
29.	Loeffler CML, Bando H, Sainath S, et al. HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer[J]. Nat Commun, 2025, 16(1): 7561.
30.	Volinsky-Fremond S, Horeweg N, Andani S, et al. Author correction: prediction of recurrence risk in endometrial cancer with multimodal deep learning[J]. Nat Med, 2024, 30(7): 2092.
31.	Lee KS, Jang JY, Yu YD, et al. Usefulness of artificial intelligence for predicting recurrence following surgery for pancreatic cancer: retrospective cohort study[J]. Int J Surg, 2021, 93: 106050.
32.	Tammem?gi MC, Darling GE, Schmidt H, et al. Risk-based lung cancer screening performance in a universal healthcare setting[J]. Nat Med, 2024, 30(4): 1054-1064.
33.	劉倫旭, 高樹庚, 何建行, 等. 非小細胞肺癌術后隨訪中國胸外科專家共識 (2025版)[J]. 中國胸心血管外科臨床雜志, 2025, 32(3): 281-290.Liu LX, Gao SG, He JX, et al. Chinese expert consensus on postoperative follow-up for non-small cell lung cancer (version 2025)[J]. Chin J Clin Thorac Cardiovasc Surg, 2025, 32(3): 281-290.
34.	Chen Y, Lehmann CU, Malin B. Digital information ecosystems in modern care coordination and patient care pathways and the challenges and opportunities for AI solutions[J]. J Med Internet Res, 2024, 26: e60258.
35.	He T, Cui W, Feng Y, et al. Digital health integration for noncommunicable diseases: comprehensive process mapping for full-life-cycle management[J]. J Evid Based Med, 2024, 17(1): 26-36.
36.	Marzo-Castillejo M, Mascort Roca J, Brau Tarrida A, et al. Participant selection for lung cancer screening using primary care electronic medical records: the Catalan scenario[J]. Aten Primaria, 2026, 58(1): 103363.
37.	Kuang Q, Feng B, Xu K, et al. Multimodal deep learning radiomics model for predicting postoperative progression in solid stage Ⅰ non-small cell lung cancer[J]. Cancer Imaging, 2024, 24(1): 140.
38.	Fu Y, Hou R, Qian L, et al. CT-based deep learning model for improved disease-free survival prediction in clinical stageⅠ lung cancer: a real-world multicenter study[J]. Eur Radiol, 2025, 35(12): 8126-8139.
39.	Zhong X, Lin H, Zhang R, et al. Development of a multi-feature predictive model for risk stratification in stage ⅠB-ⅡA non-small cell lung cancer: a multicenter analysis[J]. Eur J Radiol, 2025, 192: 112379.
40.	Huang WJ, Xie HB, Liu PP, et al. Pericardial fat and primary tumor radiomics for predicting occult N2 disease and survival in clinical stage Ⅰ non-small cell lung cancer: multicenter study and biologic correlation[J]. AJR Am J Roentgenol, 2025, 225(2): e2532861.
41.	Mehri-Kakavand G, Mdletshe S, Amini M, et al. Multimodal radiomics fusion for predicting postoperative recurrence in NSCLC patients[J]. J Cancer Res Clin Oncol, 2025, 151(10): 261.
42.	Duan F, Zhang M, Yang C, et al. Non-invasive prediction of lymph node metastasis in NSCLC using clinical, radiomics, and deep learning features from 18F-FDG PET/CT based on interpretable machine learning[J]. Acad Radiol, 2025, 32(3): 1645-1655.
43.	Deng C, Zhang Y, Fu F, et al. Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma[J]. Eur J Cardiothorac Surg, 2021, 60(5): 1223-1231.
44.	Watanabe K, Noma D, Masuda H, et al. Preoperative inflammation-based scores predict early recurrence after lung cancer resection[J]. J Thorac Dis, 2021, 13(5): 2812-2823.
45.	Bastani M, Toumazis I, Hedou' J, et al. Evaluation of alternative diagnostic follow-up intervals for Lung Reporting and Data System criteria on the effectiveness of lung cancer screening[J]. J Am Coll Radiol, 2021, 18(12): 1614-1623.
46.	Triplette MA, Wenger DS, Shahrir S, et al. Patient identification of lung cancer screening follow-up recommendations and the association with adherence[J]. Ann Am Thorac Soc, 2022, 19(5): 799-806.
47.	Rivera MP, Durham DD, Long JM, et al. Receipt of recommended follow-up care after a positive lung cancer screening examination[J]. JAMA Netw Open, 2022, 5(11): e2240403.
48.	Hill NR, Dotson TL, Maus SE, et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study[J]. BMJ Open Respir Res, 2025, 12(1): e003225.
49.	李梅, 張洪兵, 夏春秋, 等. AI賦能的專病管理平臺在肺癌患者術后康復中的應用研究[J]. 中國肺癌雜志, 2025, 28(3): 176-182.Li M, Zhang HB, Xia CQ, et al. Application practice of AI empowering post-discharge specialized disease management in postoperative rehabilitation of the lung cancer patients undergoing surgery[J]. Chin J Lung Cancer, 2025, 28(3): 176-182.
50.	Robin F, Roy M, Kuftedjian A, et al. Medico-economic evaluation of a telehealth platform for elective outpatient surgeries: randomized controlled trial[J]. J Med Internet Res, 2025, 27: e76730.
51.	Zhou Z, Jin D, He J, et al. Digital health platform for improving the effect of the active health management of chronic diseases in the community: mixed methods exploratory study[J]. J Med Internet Res, 2024, 26: e50959.
52.	Liew SL, Cotton RJ, Burdet E, et al. Collaborative AI for precision neurorehabilitation: a roadmap[J]. J Neuroeng Rehabil, 2025, 22(1): 269.
53.	Staffurth JN, Haviland JS, Wilkins A, et al. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016)[J]. Eur Urol Oncol, 2021, 4(6): 980-992.
54.	Boyajian RA, Gordon WJ, Kowtoniuk AM, et al. Development & impact of a virtual PSA monitoring clinic for follow-up of prostate cancer patients: an efficient model with unique benefits relevant to COVID-19[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3): S65.
55.	Jia X, Gao C, Da X, et al. Evaluation of an intelligent digital platform for population management in cervical cancer screening[J]. Cancer Biol Med, 2025, 22(9): 1068-1082.
56.	Lee J, Kong S, Shin S, et al. Wearable device-based intervention for promoting patient physical activity after lung cancer surgery: a nonrandomized clinical trial[J]. JAMA Netw Open, 2024, 7(9): e2434180.
57.	Lu T, Deng T, Long Y, et al. Effectiveness and feasibility of digital pulmonary rehabilitation in patients undergoing lung cancer surgery: systematic review and meta-analysis[J]. J Med Internet Res, 2024, 26: e56795.
58.	Zhou J, Muluneh B, Wang Z, et al. Leveraging longitudinal patient-reported outcome trajectories to predict survival in non-small cell lung cancer[J]. Clin Cancer Res, 2025, 31(13): 2685-2694.
59.	Dai W, Feng W, Zhang Y, et al. Patient-reported outcome-based symptom management versus usual care after lung cancer surgery: a multicenter randomized controlled trial[J]. J Clin Oncol, 2022, 40(9): 988-996.
60.	Liang Y, Jing P, Gu Z, et al. Application of the patient-reported outcome-based postoperative symptom management model in lung cancer: a multicenter randomized controlled trial protocol[J]. Trials, 2024, 25(1): 130.
61.	Wang R, Zheng J, Guo W, et al. Integrating a multimodal digital device for continuous perioperative monitoring in patients with lung cancer undergoing thoracic surgery: development and usability study[J]. JMIR Mhealth Uhealth, 2025, 13: e69512.
62.	Rossi LA, Melstrom LG, Fong Y, et al. Predicting post-discharge cancer surgery complications via telemonitoring of patient-reported outcomes and patient-generated health data[J]. J Surg Oncol, 2021, 123(5): 1345-1352.
63.	Cheng X, Yang Y, Shentu Y, et al. Remote monitoring of patient recovery following lung cancer surgery: a messenger application approach[J]. J Thorac Dis, 2021, 13(2): 1162-1171.
64.	García Abejas A, Serra Trullás A, Sobral MA, et al. Improving the understanding and managing of the quality of life of patients with lung cancer with electronic patient-reported outcome measures: scoping review[J]. J Med Internet Res, 2023, 25: e46259.
65.	Dai W, Wang Y, Liao J, et al. Electronic patient-reported outcome-based symptom management versus usual care after lung cancer surgery: long-term results of a multicenter, randomized, controlled trial[J]. J Clin Oncol, 2024, 42(18): 2126-2131.
66.	Xu J, Ni H, Zhan H, et al. Efficacy of digital therapeutics for perioperative management in patients with lung cancer: a randomized controlled trial[J]. BMC Med, 2025, 23(1): 186.
67.	Elkefi S, Wu P, Sabra R, et al. Systematic review on the technology's role in supporting lung cancer patients in the treatment journey[J]. NPJ Digit Med, 2025, 8(1): 516.
68.	Kirkpatrick S, Davey Z, Wright PR, et al. Supportive ehealth technologies and their effects on physical functioning and quality of life for people with lung cancer: systematic review[J]. J Med Internet Res, 2024, 26: e53015.
69.	Xie S, Li M, Li R, et al. Electronic patient-reported outcomes for outpatient care after non-intubated thoracic surgery in early-stage lung cancer[J]. J Thorac Dis, 2025, 17(11): 9847-9855.
70.	Majem M, Basch E, Cella D, et al. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: a review[J]. Lung Cancer, 2024, 187: 107419.
71.	Murota M, Norikane T, Ishimura M, et al. Beyond resection: imaging findings of expected and complicated postoperative changes in lung cancer[J]. Jpn J Radiol, 2025, 43(10): 1590-1605.
72.	Philip B, Jain A, Ramesh P, et al. Follow up and surveillance post lung cancer surgery: a narrative review[J]. Video-Assist Thorac Surg, 2023, 8: 7.
73.	Xu D, de la Hoz RE, Steinberger SR, et al. Postoperative CT surveillance in the evaluation of local recurrence after sub-lobar resection of neoplastic lesions of the lung[J]. Clin Imaging, 2024, 106: 110030.
74.	Murphy DJ, Gill RR. Radiographic assessment of small lung nodules: what can we do and what information does it give us[J]? Curr Challen Thorac Surg, 2022, 4: 32.
75.	Leiro-Fernández V, Fernández-Villar A. Mediastinal staging for non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 496-505.
76.	Kim SJ, Lee KH, Lee HJ, et al. Maximum standardized uptake value-to-tumor size ratio in fluorodeoxyglucose F18 positron emission tomography/computed tomography: a simple prognostic parameter for non-small cell lung cancer[J]. Diagn Interv Radiol, 2025, 31(3): 274-279.
77.	Gao C, Wu L, Wu W, et al. Deep learning in pulmonary nodule detection and segmentation: a systematic review[J]. Eur Radiol, 2025, 35(1): 255-266.
78.	Jiang B, Lancaster HL, Davies MPA, et al. AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation[J]. Eur J Cancer, 2026, 232: 116137.
79.	Hendrix W, Hendrix N, Scholten ET, et al. Deep learning for the detection of benign and malignant pulmonary nodules in non-screening chest CT scans[J]. Commun Med (Lond), 2023, 3(1): 156.
80.	Jang S, Kim J, Lee JS, et al. Real-world diagnostic performance and clinical utility of artificial intelligence-assisted interpretation for detection of lung metastasis on CT in patients with colorectal cancer[J]. AJR Am J Roentgenol, 2025, 225(3): e2533063.
81.	Tyagi S, Talbar SN. CSE-GAN: a 3D conditional generative adversarial network with concurrent squeeze-and-excitation blocks for lung nodule segmentation[J]. Comput Biol Med, 2022, 147: 105781.
82.	Chen L, Gu D, Chen Y, et al. An artificial-intelligence lung imaging analysis system (ALIAS) for population-based nodule computing in CT scans[J]. Comput Med Imaging Graph, 2021, 89: 101899.
83.	Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution[J]. Nature, 2017, 545(7655): 446-451.
84.	Lv C, Lu F, Zhou X, et al. Efficacy of a smartphone application assisting home-based rehabilitation and symptom management for patients with lung cancer undergoing video-assisted thoracoscopic lobectomy: a prospective, single-blinded, randomised control trial (POPPER study)[J]. Int J Surg, 2025, 111(1): 597-608.
85.	Wang C, Shao J, He Y, et al. Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography[J]. Nat Med, 2024, 30(11): 3184-3195.
86.	Feng Y, Dai W, Wang Y, et al. Comparison of chief complaints and patient-reported symptoms of treatment-naive lung cancer patients before surgery[J]. Patient Prefer Adherence, 2021, 15: 1101-1106.
87.	楊麗, 王婷, 敖敏, 等. 肺結節與肺癌全程智能管理云平臺的構建及臨床應用[J]. 中華肺部疾病雜志(電子版), 2022, 15(1): 11-14.Yang L, Wang T, Ao M, et al. Construction and clinical application of cloud platform for intelligent management of lung nodules and lung cancer[J]. Chin J Lung Dis (Electron Ed), 2022, 15(1): 11-14.
88.	Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer[J]. Clin Cancer Res, 2021, 27(20): 5586-5594.
89.	Billingy NE, van den Hurk CJG, Tromp V, et al. Patient- vs physician-initiated response to symptom monitoring and health-related quality of life: the SYMPRO-Lung cluster randomized trial[J]. JAMA Netw Open, 2024, 7(8): e2428975.
90.	Yu H, Lei C, Wei X, et al. Electronic symptom monitoring after lung cancer surgery: establishing a core set of patient-reported outcomes for surgical oncology care in a longitudinal cohort study[J]. Int J Surg, 2024, 110(10): 6591-6600.
91.	Xia Y, Guan X, Zhu W, et al. Effectiveness of symptom monitoring on electronic patient-reported outcomes (ePROs) among patients with lung cancer: a systematic review and meta-analysis[J]. NPJ Digit Med, 2025, 8(1): 399.
92.	中華醫學會腫瘤學分會. 中華醫學會肺癌臨床診療指南(2025版)[J]. 中華腫瘤雜志, 2025, 47(9): 769-810.Oncology Society of Chinese Medical Association. Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)[J]. Chin J Oncol, 2025, 47(9): 769-810.
93.	Denis F, Basch E, Septans AL, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer[J]. JAMA, 2019, 321(3): 306-307.
94.	Wang S, Xia Z, You J, et al. Enhanced detection of landmark minimal residual disease in lung cancer using cell-free DNA fragmentomics[J]. Cancer Res Commun, 2023, 3(5): 933-942.
95.	Wei Y, Wang L, Jin Z, et al. Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review[J]. Transl Lung Cancer Res, 2024, 13(3): 635-653.
96.	Nam JG, Park S, Park CM, et al. Histopathologic basis for a chest CT deep learning survival prediction model in patients with lung adenocarcinoma[J]. Radiology, 2022, 305(2): 441-451.
97.	Koutoulakis E, Trivizakis E, Markodimitrakis E, et al. A critical review of explainable deep learning in lung cancer diagnosis[J]. Artif Intell Rev, 2025, 59(1): 28.
98.	Xu J, Feng B, Chen X, et al. A generalized heterogeneous federated model for identifying patients with postoperative progression of early-stage non-small cell lung cancer[J]. Sci Rep, 2025, 16(1): 910.
99.	Abbosh C, Hodgson D, Doherty GJ, et al. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer[J]. Trends Cancer, 2024, 10(7): 643-654.
100.	Schuurbiers MMF, Smith CG, Hartemink KJ, et al. Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study[J]. PLoS Med, 2025, 22(4): e1004574.

1. Leivaditis V, Maniatopoulos AA, Lausberg H, et al. Artificial intelligence in thoracic surgery: a review bridging innovation and clinical practice for the next generation of surgical care[J]. J Clin Med, 2025, 14(8): 2729.
2. Huang D, Li Z, Jiang T, et al. Artificial intelligence in lung cancer: current applications, future perspectives, and challenges[J]. Front Oncol, 2024, 14: 1486310.
3. Gandhi Z, Gurram P, Amgai B, et al. Artificial intelligence and lung cancer: impact on improving patient outcomes[J]. Cancers (Basel), 2023, 15(21): 5236.
4. Lococo F, Ghaly G, Flamini S, et al. Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives[J]. J Thorac Dis, 2024, 16(10): 7096-7110.
5. Li Y, Chai X, Yang M, et al. Accurate prediction of disease-free and overall survival in non-small cell lung cancer using patient-level multimodal weakly supervised learning[J]. NPJ Precis Oncol, 2025, 9(1): 197.
6. Jung HA, Lee DY, Park BG, et al. Deep-learning model for real-time prediction of recurrence in early-stage non-small cell lung cancer: a multimodal approach (RADAR CARE Study)[J]. JCO Precis Oncol, 2025, 9: e2500172.
7. Jin Y, Mu W, Shi Y, et al. Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG)[J]. EClinicalMedicine, 2024, 75: 102769.
8. Baptiste JV. Process improvement for clinical follow-up of incidental lung nodules: a practical perspective[J]. Chest, 2026, 169(4): 1135-1141.
9. Heiden BT, Eaton DB, Chang SH, et al. Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer[J]. J Natl Cancer Inst, 2023, 115(3): 303-310.
10. Jin W, Shen L, Tian Y, et al. Improving the prediction of spreading through air spaces (STAS) in primary lung cancer with a dynamic dual-delta hybrid machine learning model: a multicenter cohort study[J]. Biomark Res, 2023, 11(1): 102.
11. Sasaki Y, Kondo Y, Aoki T, et al. Use of deep learning to predict postoperative recurrence of lung adenocarcinoma from preoperative CT[J]. Int J Comput Assist Radiol Surg, 2022, 17(9): 1651-1661.
12. Akram F, Wolf JL, Trandafir TE, et al. Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies[J]. Lung Cancer, 2023, 186: 107413.
13. Shimada Y, Kudo Y, Maehara S, et al. Artificial intelligence-based radiomics for the prediction of nodal metastasis in early-stage lung cancer[J]. Sci Rep, 2023, 13(1): 1028.
14. Kinoshita F, Takenaka T, Yamashita T, et al. Development of artificial intelligence prognostic model for surgically resected non-small cell lung cancer[J]. Sci Rep, 2023, 13(1): 15683.
15. Pu L, Dhupar R, Meng X. Predicting postoperative lung cancer recurrence and survival using Cox proportional hazards regression and machine learning[J]. Cancers (Basel), 2024, 17(1): 33.
16. Na KJ, Kim YT, Goo JM, et al. Clinical utility of a CT-based AI prognostic model for segmentectomy in non-small cell lung cancer[J]. Radiology, 2024, 311(1): e231793.
17. Tominaga M, Yamazaki M, Umezu H, et al. Prognostic value and pathological correlation of peritumoral radiomics in surgically resected non-small cell lung cancer[J]. Acad Radiol, 2024, 31(9): 3801-3810.
18. Zhao X, Wang Y, Xue M, et al. Preoperative assessment of tertiary lymphoid structures in stage Ⅰ lung adenocarcinoma using CT radiomics: a multicenter retrospective cohort study[J]. Cancer Imaging, 2024, 24(1): 167.
19. Sujit SJ, Aminu M, Karpinets TV, et al. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights[J]. Nat Commun, 2024, 15(1): 3152.
20. Niu Y, Xie HB, Jia HB, et al. Multimodal deep learning integrating tumor radiomics and mediastinal adiposity improves survival prediction in non-small cell lung cancer: a prognostic modeling study[J]. Cancer Med, 2025, 14(15): e71077.
21. Amini M, Hajianfar G, Salimi Y, et al. MetaPredictomics: a comprehensive approach to predict postsurgical non-small cell lung cancer recurrence using clinicopathologic, radiomics, and organomics data[J]. Clin Nucl Med, 2025, 50(12): 1130-1143.
22. Yan H, Niimi T, Matsunaga T, et al. Preoperatively predicting survival outcome for clinical stage ⅠA pure-solid non-small cell lung cancer by radiomics-based machine learning[J]. J Thorac Cardiovasc Surg, 2025.
23. Janik A, Torrente M, Costabello L, et al. Machine learning-assisted recurrence prediction for patients with early-stage non-small-cell lung cancer[J]. JCO Clin Cancer Inform, 2023, 7: e2200062.
24. 王志林, 朱曉雷, 張瀟文, 等. 人工智能在非小細胞肺癌病理學和預后中應用的研究進展[J]. 中國胸心血管外科臨床雜志, 2022, 29(9): 1223-1229.Wang ZL, Zhu XL, Zhang XW, et al. Research progress on the application of artificial intelligence in the pathology and prognosis of non-small cell lung cancer[J]. Chin J Clin Thorac Cardiovasc Surg, 2022, 29(9): 1223-1229.
25. 馮時, 滕曉東. 人工智能在肺癌病理精準診斷中的研究進展[J]. 中國胸心血管外科臨床雜志, 2021, 28(5): 592-596.Feng S, Teng XD. Research progress on artificial intelligence in precise pathological diagnosis of lung cancer[J]. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(5): 592-596.
26. Mehri-Kakavand G, Mdletshe S, Wang A. A comprehensive review on the application of artificial intelligence for predicting postsurgical recurrence risk in early-stage non-small cell lung cancer using computed tomography, positron emission tomography, and clinical data[J]. J Med Radiat Sci, 2025, 72(3): 280-296.
27. Zhang D, Wu Y, Xu Y, et al. Development of a postoperative recurrence prediction model for stage Ⅰ non-small cell lung cancer patients using multimodal data based on machine learning[J]. J Army Med Univ, 2025, 47(14): 1602-1611.
28. Kwok WC, Ma TF, Ho JCM, et al. Prediction model on disease recurrence for low risk resected stageⅠ lung adenocarcinoma[J]. Respirology, 2023, 28(7): 669-676.
29. Loeffler CML, Bando H, Sainath S, et al. HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer[J]. Nat Commun, 2025, 16(1): 7561.
30. Volinsky-Fremond S, Horeweg N, Andani S, et al. Author correction: prediction of recurrence risk in endometrial cancer with multimodal deep learning[J]. Nat Med, 2024, 30(7): 2092.
31. Lee KS, Jang JY, Yu YD, et al. Usefulness of artificial intelligence for predicting recurrence following surgery for pancreatic cancer: retrospective cohort study[J]. Int J Surg, 2021, 93: 106050.
32. Tammem?gi MC, Darling GE, Schmidt H, et al. Risk-based lung cancer screening performance in a universal healthcare setting[J]. Nat Med, 2024, 30(4): 1054-1064.
33. 劉倫旭, 高樹庚, 何建行, 等. 非小細胞肺癌術后隨訪中國胸外科專家共識 (2025版)[J]. 中國胸心血管外科臨床雜志, 2025, 32(3): 281-290.Liu LX, Gao SG, He JX, et al. Chinese expert consensus on postoperative follow-up for non-small cell lung cancer (version 2025)[J]. Chin J Clin Thorac Cardiovasc Surg, 2025, 32(3): 281-290.
34. Chen Y, Lehmann CU, Malin B. Digital information ecosystems in modern care coordination and patient care pathways and the challenges and opportunities for AI solutions[J]. J Med Internet Res, 2024, 26: e60258.
35. He T, Cui W, Feng Y, et al. Digital health integration for noncommunicable diseases: comprehensive process mapping for full-life-cycle management[J]. J Evid Based Med, 2024, 17(1): 26-36.
36. Marzo-Castillejo M, Mascort Roca J, Brau Tarrida A, et al. Participant selection for lung cancer screening using primary care electronic medical records: the Catalan scenario[J]. Aten Primaria, 2026, 58(1): 103363.
37. Kuang Q, Feng B, Xu K, et al. Multimodal deep learning radiomics model for predicting postoperative progression in solid stage Ⅰ non-small cell lung cancer[J]. Cancer Imaging, 2024, 24(1): 140.
38. Fu Y, Hou R, Qian L, et al. CT-based deep learning model for improved disease-free survival prediction in clinical stageⅠ lung cancer: a real-world multicenter study[J]. Eur Radiol, 2025, 35(12): 8126-8139.
39. Zhong X, Lin H, Zhang R, et al. Development of a multi-feature predictive model for risk stratification in stage ⅠB-ⅡA non-small cell lung cancer: a multicenter analysis[J]. Eur J Radiol, 2025, 192: 112379.
40. Huang WJ, Xie HB, Liu PP, et al. Pericardial fat and primary tumor radiomics for predicting occult N2 disease and survival in clinical stage Ⅰ non-small cell lung cancer: multicenter study and biologic correlation[J]. AJR Am J Roentgenol, 2025, 225(2): e2532861.
41. Mehri-Kakavand G, Mdletshe S, Amini M, et al. Multimodal radiomics fusion for predicting postoperative recurrence in NSCLC patients[J]. J Cancer Res Clin Oncol, 2025, 151(10): 261.
42. Duan F, Zhang M, Yang C, et al. Non-invasive prediction of lymph node metastasis in NSCLC using clinical, radiomics, and deep learning features from 18F-FDG PET/CT based on interpretable machine learning[J]. Acad Radiol, 2025, 32(3): 1645-1655.
43. Deng C, Zhang Y, Fu F, et al. Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma[J]. Eur J Cardiothorac Surg, 2021, 60(5): 1223-1231.
44. Watanabe K, Noma D, Masuda H, et al. Preoperative inflammation-based scores predict early recurrence after lung cancer resection[J]. J Thorac Dis, 2021, 13(5): 2812-2823.
45. Bastani M, Toumazis I, Hedou' J, et al. Evaluation of alternative diagnostic follow-up intervals for Lung Reporting and Data System criteria on the effectiveness of lung cancer screening[J]. J Am Coll Radiol, 2021, 18(12): 1614-1623.
46. Triplette MA, Wenger DS, Shahrir S, et al. Patient identification of lung cancer screening follow-up recommendations and the association with adherence[J]. Ann Am Thorac Soc, 2022, 19(5): 799-806.
47. Rivera MP, Durham DD, Long JM, et al. Receipt of recommended follow-up care after a positive lung cancer screening examination[J]. JAMA Netw Open, 2022, 5(11): e2240403.
48. Hill NR, Dotson TL, Maus SE, et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study[J]. BMJ Open Respir Res, 2025, 12(1): e003225.
49. 李梅, 張洪兵, 夏春秋, 等. AI賦能的專病管理平臺在肺癌患者術后康復中的應用研究[J]. 中國肺癌雜志, 2025, 28(3): 176-182.Li M, Zhang HB, Xia CQ, et al. Application practice of AI empowering post-discharge specialized disease management in postoperative rehabilitation of the lung cancer patients undergoing surgery[J]. Chin J Lung Cancer, 2025, 28(3): 176-182.
50. Robin F, Roy M, Kuftedjian A, et al. Medico-economic evaluation of a telehealth platform for elective outpatient surgeries: randomized controlled trial[J]. J Med Internet Res, 2025, 27: e76730.
51. Zhou Z, Jin D, He J, et al. Digital health platform for improving the effect of the active health management of chronic diseases in the community: mixed methods exploratory study[J]. J Med Internet Res, 2024, 26: e50959.
52. Liew SL, Cotton RJ, Burdet E, et al. Collaborative AI for precision neurorehabilitation: a roadmap[J]. J Neuroeng Rehabil, 2025, 22(1): 269.
53. Staffurth JN, Haviland JS, Wilkins A, et al. Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016)[J]. Eur Urol Oncol, 2021, 4(6): 980-992.
54. Boyajian RA, Gordon WJ, Kowtoniuk AM, et al. Development & impact of a virtual PSA monitoring clinic for follow-up of prostate cancer patients: an efficient model with unique benefits relevant to COVID-19[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3): S65.
55. Jia X, Gao C, Da X, et al. Evaluation of an intelligent digital platform for population management in cervical cancer screening[J]. Cancer Biol Med, 2025, 22(9): 1068-1082.
56. Lee J, Kong S, Shin S, et al. Wearable device-based intervention for promoting patient physical activity after lung cancer surgery: a nonrandomized clinical trial[J]. JAMA Netw Open, 2024, 7(9): e2434180.
57. Lu T, Deng T, Long Y, et al. Effectiveness and feasibility of digital pulmonary rehabilitation in patients undergoing lung cancer surgery: systematic review and meta-analysis[J]. J Med Internet Res, 2024, 26: e56795.
58. Zhou J, Muluneh B, Wang Z, et al. Leveraging longitudinal patient-reported outcome trajectories to predict survival in non-small cell lung cancer[J]. Clin Cancer Res, 2025, 31(13): 2685-2694.
59. Dai W, Feng W, Zhang Y, et al. Patient-reported outcome-based symptom management versus usual care after lung cancer surgery: a multicenter randomized controlled trial[J]. J Clin Oncol, 2022, 40(9): 988-996.
60. Liang Y, Jing P, Gu Z, et al. Application of the patient-reported outcome-based postoperative symptom management model in lung cancer: a multicenter randomized controlled trial protocol[J]. Trials, 2024, 25(1): 130.
61. Wang R, Zheng J, Guo W, et al. Integrating a multimodal digital device for continuous perioperative monitoring in patients with lung cancer undergoing thoracic surgery: development and usability study[J]. JMIR Mhealth Uhealth, 2025, 13: e69512.
62. Rossi LA, Melstrom LG, Fong Y, et al. Predicting post-discharge cancer surgery complications via telemonitoring of patient-reported outcomes and patient-generated health data[J]. J Surg Oncol, 2021, 123(5): 1345-1352.
63. Cheng X, Yang Y, Shentu Y, et al. Remote monitoring of patient recovery following lung cancer surgery: a messenger application approach[J]. J Thorac Dis, 2021, 13(2): 1162-1171.
64. García Abejas A, Serra Trullás A, Sobral MA, et al. Improving the understanding and managing of the quality of life of patients with lung cancer with electronic patient-reported outcome measures: scoping review[J]. J Med Internet Res, 2023, 25: e46259.
65. Dai W, Wang Y, Liao J, et al. Electronic patient-reported outcome-based symptom management versus usual care after lung cancer surgery: long-term results of a multicenter, randomized, controlled trial[J]. J Clin Oncol, 2024, 42(18): 2126-2131.
66. Xu J, Ni H, Zhan H, et al. Efficacy of digital therapeutics for perioperative management in patients with lung cancer: a randomized controlled trial[J]. BMC Med, 2025, 23(1): 186.
67. Elkefi S, Wu P, Sabra R, et al. Systematic review on the technology's role in supporting lung cancer patients in the treatment journey[J]. NPJ Digit Med, 2025, 8(1): 516.
68. Kirkpatrick S, Davey Z, Wright PR, et al. Supportive ehealth technologies and their effects on physical functioning and quality of life for people with lung cancer: systematic review[J]. J Med Internet Res, 2024, 26: e53015.
69. Xie S, Li M, Li R, et al. Electronic patient-reported outcomes for outpatient care after non-intubated thoracic surgery in early-stage lung cancer[J]. J Thorac Dis, 2025, 17(11): 9847-9855.
70. Majem M, Basch E, Cella D, et al. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: a review[J]. Lung Cancer, 2024, 187: 107419.
71. Murota M, Norikane T, Ishimura M, et al. Beyond resection: imaging findings of expected and complicated postoperative changes in lung cancer[J]. Jpn J Radiol, 2025, 43(10): 1590-1605.
72. Philip B, Jain A, Ramesh P, et al. Follow up and surveillance post lung cancer surgery: a narrative review[J]. Video-Assist Thorac Surg, 2023, 8: 7.
73. Xu D, de la Hoz RE, Steinberger SR, et al. Postoperative CT surveillance in the evaluation of local recurrence after sub-lobar resection of neoplastic lesions of the lung[J]. Clin Imaging, 2024, 106: 110030.
74. Murphy DJ, Gill RR. Radiographic assessment of small lung nodules: what can we do and what information does it give us[J]? Curr Challen Thorac Surg, 2022, 4: 32.
75. Leiro-Fernández V, Fernández-Villar A. Mediastinal staging for non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 496-505.
76. Kim SJ, Lee KH, Lee HJ, et al. Maximum standardized uptake value-to-tumor size ratio in fluorodeoxyglucose F18 positron emission tomography/computed tomography: a simple prognostic parameter for non-small cell lung cancer[J]. Diagn Interv Radiol, 2025, 31(3): 274-279.
77. Gao C, Wu L, Wu W, et al. Deep learning in pulmonary nodule detection and segmentation: a systematic review[J]. Eur Radiol, 2025, 35(1): 255-266.
78. Jiang B, Lancaster HL, Davies MPA, et al. AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation[J]. Eur J Cancer, 2026, 232: 116137.
79. Hendrix W, Hendrix N, Scholten ET, et al. Deep learning for the detection of benign and malignant pulmonary nodules in non-screening chest CT scans[J]. Commun Med (Lond), 2023, 3(1): 156.
80. Jang S, Kim J, Lee JS, et al. Real-world diagnostic performance and clinical utility of artificial intelligence-assisted interpretation for detection of lung metastasis on CT in patients with colorectal cancer[J]. AJR Am J Roentgenol, 2025, 225(3): e2533063.
81. Tyagi S, Talbar SN. CSE-GAN: a 3D conditional generative adversarial network with concurrent squeeze-and-excitation blocks for lung nodule segmentation[J]. Comput Biol Med, 2022, 147: 105781.
82. Chen L, Gu D, Chen Y, et al. An artificial-intelligence lung imaging analysis system (ALIAS) for population-based nodule computing in CT scans[J]. Comput Med Imaging Graph, 2021, 89: 101899.
83. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution[J]. Nature, 2017, 545(7655): 446-451.
84. Lv C, Lu F, Zhou X, et al. Efficacy of a smartphone application assisting home-based rehabilitation and symptom management for patients with lung cancer undergoing video-assisted thoracoscopic lobectomy: a prospective, single-blinded, randomised control trial (POPPER study)[J]. Int J Surg, 2025, 111(1): 597-608.
85. Wang C, Shao J, He Y, et al. Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography[J]. Nat Med, 2024, 30(11): 3184-3195.
86. Feng Y, Dai W, Wang Y, et al. Comparison of chief complaints and patient-reported symptoms of treatment-naive lung cancer patients before surgery[J]. Patient Prefer Adherence, 2021, 15: 1101-1106.
87. 楊麗, 王婷, 敖敏, 等. 肺結節與肺癌全程智能管理云平臺的構建及臨床應用[J]. 中華肺部疾病雜志(電子版), 2022, 15(1): 11-14.Yang L, Wang T, Ao M, et al. Construction and clinical application of cloud platform for intelligent management of lung nodules and lung cancer[J]. Chin J Lung Dis (Electron Ed), 2022, 15(1): 11-14.
88. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer[J]. Clin Cancer Res, 2021, 27(20): 5586-5594.
89. Billingy NE, van den Hurk CJG, Tromp V, et al. Patient- vs physician-initiated response to symptom monitoring and health-related quality of life: the SYMPRO-Lung cluster randomized trial[J]. JAMA Netw Open, 2024, 7(8): e2428975.
90. Yu H, Lei C, Wei X, et al. Electronic symptom monitoring after lung cancer surgery: establishing a core set of patient-reported outcomes for surgical oncology care in a longitudinal cohort study[J]. Int J Surg, 2024, 110(10): 6591-6600.
91. Xia Y, Guan X, Zhu W, et al. Effectiveness of symptom monitoring on electronic patient-reported outcomes (ePROs) among patients with lung cancer: a systematic review and meta-analysis[J]. NPJ Digit Med, 2025, 8(1): 399.
92. 中華醫學會腫瘤學分會. 中華醫學會肺癌臨床診療指南(2025版)[J]. 中華腫瘤雜志, 2025, 47(9): 769-810.Oncology Society of Chinese Medical Association. Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)[J]. Chin J Oncol, 2025, 47(9): 769-810.
93. Denis F, Basch E, Septans AL, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer[J]. JAMA, 2019, 321(3): 306-307.
94. Wang S, Xia Z, You J, et al. Enhanced detection of landmark minimal residual disease in lung cancer using cell-free DNA fragmentomics[J]. Cancer Res Commun, 2023, 3(5): 933-942.
95. Wei Y, Wang L, Jin Z, et al. Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review[J]. Transl Lung Cancer Res, 2024, 13(3): 635-653.
96. Nam JG, Park S, Park CM, et al. Histopathologic basis for a chest CT deep learning survival prediction model in patients with lung adenocarcinoma[J]. Radiology, 2022, 305(2): 441-451.
97. Koutoulakis E, Trivizakis E, Markodimitrakis E, et al. A critical review of explainable deep learning in lung cancer diagnosis[J]. Artif Intell Rev, 2025, 59(1): 28.
98. Xu J, Feng B, Chen X, et al. A generalized heterogeneous federated model for identifying patients with postoperative progression of early-stage non-small cell lung cancer[J]. Sci Rep, 2025, 16(1): 910.
99. Abbosh C, Hodgson D, Doherty GJ, et al. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer[J]. Trends Cancer, 2024, 10(7): 643-654.
100. Schuurbiers MMF, Smith CG, Hartemink KJ, et al. Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study[J]. PLoS Med, 2025, 22(4): e1004574.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Latest ArticlesAdvances and challenges of artificial intelligence in postoperative follow-up management of lung cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content